In conclusion, these results suggest a close association between the expression level of SLC7A11 and the sensitivity of ACC patients to anti-tumor drugs, implying a potentially significant role of SLC7A11 in the treatment of ACC. This evidence concerns the gene SLC7A11 and adrenal cortex carcinoma.